ERBB2 and breast cancer: In the phase IIIb KAMILLA trial T-DM1, the first ADC approved for the treatment of metastatic HER2-positive BC, yielded an intracranial response rate of 49.3% (33/67; 95% CI: 36.9–61.8) in the subset of patients with measurable BM without prior radiotherapy.